Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06128278 · ClinicalTrials.gov registry record · Phase 2
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
A Phase 2 study of Chronic Kidney Diseases and Women, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT06128278: Recruiting Phase 2 study of Chronic Kidney Diseases and Women, sponsored by University of Colorado, Denver.
NCT06128278 is a Phase 2 study of Chronic Kidney Diseases and Women that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 38 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06128278, a Phase 2 study of Chronic Kidney Diseases and Women, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literature in nephrology focuses on male patients, and studies on women's vascular health are limited. Establishing effective therapies for improving vascular function and reducing CVD risk in women with CKD is a high research priority of the NIH. Equol contributes to improvement in vascular function, mediated in part by its anti-oxidative and anti-inflammatory properties. However, there is no information on the effect of equol on vascular function in women with CKD. The proposed project aims to determine the acute effect (1-hour, 2-hours, and 3-hours post ingestion) of oral equol supplementation on vascular function in postmenopausal women with and without CKD.
Primary Outcome
Flow-mediated dilation of the brachial artery will be performed using ultrasonography and analyzed with a commercially available software package as percent change in diameter from baseline following reactive hyperemia.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG S-equol
Study Locations (1)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06128278 shows while recruiting
NCT06128278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (91% lower).
The record links to 3 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06128278 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06128278 about?
NCT06128278 is a clinical study titled "Acute Equol Supplementation and Vascular Function in Women With and Without CKD". The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk. However, most of the literatu...
What is the current status of trial NCT06128278?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2023-03-07. Estimated completion is 2026-12-31.
What conditions does trial NCT06128278 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Women, Vascular Function.
What interventions are being tested in trial NCT06128278?
The interventions under investigation include: Placebo (OTHER), S-equol (DRUG).
Who is sponsoring clinical trial NCT06128278?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06128278 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06128278's enrollment target sits among peer trials
38 59th of 73 higher than 15 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
-
Bone in CKD Alkali Response (BICARb Pilot Trial)
RECRUITING · Phase 2
-
Combination of Novel Therapies for CKD Comorbid Depression
RECRUITING · Phase 2
-
Sit Less, Interact and Move More (SLIMM) 2 Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI